ArticleCells2020
The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07183020 (Prospective, Multicentric, Real-world Investigation of Kappa Free Light Chains), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Multicentric, Real-world Investigation of Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Cerebrospinal Fluid sCD27 as a Biomarker of Neuroinflammatory Disease: A Systematic Review and Meta-Analysis.Journal of neurochemistry · 2026Pooled it
- Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2026Observational
- Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.Neurology · 2026Article
- Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.Journal of neurology · 2026Article
- Kappa free light chain index in multiple sclerosis and other inflammatory CNS diseases: a pilot single-center study from Argentina.Frontiers in immunology · 2026Article
- Kappa index: real-world study for assessing cut-off values that provide the best accuracy for multiple sclerosis diagnosis in patients with CIS.Frontiers in immunology · 2026Article
- Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.Neurological research and practice · 2025Article
- Kappa Free Light Chain Index Correlates With Prognostic Biomarkers in Multiple Sclerosis and Decreases Slowly Following Treatment.European journal of neurology · 2025Article
- The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.Neurology and therapy · 2025Review
- Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis.Frontiers in immunology · 2025Article
- Serum Neurofilament and Free Light Chain Levels in Patients Undergoing Treatment for Chronic Inflammatory Demyelinating Polyneuropathy.International journal of molecular sciences · 2024Article
- Inter-assay diagnostic accuracy of cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis.Frontiers in immunology · 2024Article
- The role of intrathecal free light chains kappa for the detection of autoimmune encephalitis in subacute onset neuropsychiatric syndromes.Scientific reports · 2023Article
- Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Biomarkers in autoimmune diseases of the central nervous system.Frontiers in immunology · 2023Review
- High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2023Article
- Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis.Frontiers in immunology · 2023Article
- Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity.Wiener medizinische Wochenschrift (1946) · 2022Review
- Saliva Free Light Chains in Patients with Neuro-Sjögren.Biomedicines · 2022Article
- Kappa Free Light Chains in Cerebrospinal Fluid in Inflammatory and Non-Inflammatory Neurological Diseases.Brain sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKappa free light chains (KFLC) are a promising new biomarker to detect neuroinflammation. Still, the impact of pre-analytical effects on KFLC concentrations was not investigated.
methodsKFLC concentrations were measured in serum and cerebrospinal fluid (CSF) of patients with a newly diagnosed multiple sclerosis (MS) or clinically isolated syndrome (CIS) before (n = 42) or after therapy with high-dose methylprednisolone (n = 65). In prospective experiments, KFLC concentrations were analyzed in the same patients in serum before and after treatment with high-dose methylprednisolone (n = 16), plasma exchange (n = 12), immunoadsorption (n = 10), or intravenous immunoglobulins (n = 10). In addition, the influence of storage time, sample method, and contamination of CSF with blood were investigated.
resultsPatients diagnosed with MS/CIS and treated with methylprednisolone showed significantly lower KFLC concentrations in serum as untreated patients. Repeated longitudinal investigations revealed that serum KFLC concentrations continuously decreased after each application of methylprednisolone. In contrast, other immune therapies and further pre-analytical conditions did not influence KFLC concentrations.
conclusionOur results show prominent effects of steroids on KFLC concentrations. In contrast, various other pre-analytical conditions did not influence KFLC concentrations, indicating the stability of this biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.